Lazar V, Raymond E, Magidi S, Bresson C, Wunder F, Berindan-Neagoe I
Ther Adv Med Oncol. 2024; 16:17588359241289200.
PMID: 39429467
PMC: 11487509.
DOI: 10.1177/17588359241289200.
Karabacak M, Jagtiani P, Di L, Shah A, Komotar R, Margetis K
Neurooncol Adv. 2024; 6(1):vdae096.
PMID: 38983675
PMC: 11232516.
DOI: 10.1093/noajnl/vdae096.
Li J, Wang C, Cheng C
Int J Cancer. 2024; 155(9):1684-1695.
PMID: 38874435
PMC: 11537842.
DOI: 10.1002/ijc.35057.
Zhang L, Liu Q, Guo Y, Tian L, Chen K, Bai D
J Nanobiotechnology. 2024; 22(1):189.
PMID: 38632615
PMC: 11025223.
DOI: 10.1186/s12951-024-02445-0.
Tschodu D, Lippoldt J, Gottheil P, Wegscheider A, Kas J, Niendorf A
Sci Rep. 2023; 13(1):16402.
PMID: 37798300
PMC: 10556090.
DOI: 10.1038/s41598-023-41090-9.
A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology.
Lazar V, Zhang B, Magidi S, Le Tourneau C, Raymond E, Ducreux M
Ther Adv Med Oncol. 2023; 15:17588359231156382.
PMID: 37025260
PMC: 10071163.
DOI: 10.1177/17588359231156382.
Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma.
Weaver C, Bin Satter K, Richardson K, Tran L, Tran P, Purohit S
Biomedicines. 2022; 10(11).
PMID: 36428521
PMC: 9687861.
DOI: 10.3390/biomedicines10112953.
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.
Lazar V, Girard N, Raymond E, Martini J, Galbraith S, Raynaud J
JCO Precis Oncol. 2022; 6:e2200072.
PMID: 36108261
PMC: 9489166.
DOI: 10.1200/PO.22.00072.
A Novel Hybrid Deep Learning Model for Metastatic Cancer Detection.
Ahmad S, Ullah T, Ahmad I, Al-Sharabi A, Ullah K, Khan R
Comput Intell Neurosci. 2022; 2022:8141530.
PMID: 35785076
PMC: 9249449.
DOI: 10.1155/2022/8141530.
Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature.
Tschodu D, Ulm B, Bendrat K, Lippoldt J, Gottheil P, Kas J
PLoS One. 2022; 17(2):e0261035.
PMID: 35143511
PMC: 8830616.
DOI: 10.1371/journal.pone.0261035.
Artificial intelligence, molecular subtyping, biomarkers, and precision oncology.
Shen J
Emerg Top Life Sci. 2021; 5(6):747-756.
PMID: 34881776
PMC: 8786277.
DOI: 10.1042/ETLS20210212.
An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients.
Guo C, Dong C, Zhang J, Wang R, Wang Z, Zhou J
Front Med (Lausanne). 2021; 8:716869.
PMID: 34350203
PMC: 8326446.
DOI: 10.3389/fmed.2021.716869.
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival.
Lazar V, Magidi S, Girard N, Savignoni A, Martini J, Massimini G
NPJ Precis Oncol. 2021; 5(1):33.
PMID: 33911192
PMC: 8080819.
DOI: 10.1038/s41698-021-00171-6.
Breath analysis based early gastric cancer classification from deep stacked sparse autoencoder neural network.
Aqeel Aslam M, Xue C, Chen Y, Zhang A, Liu M, Wang K
Sci Rep. 2021; 11(1):4014.
PMID: 33597551
PMC: 7889910.
DOI: 10.1038/s41598-021-83184-2.
Machine learning applications in drug development.
Reda C, Kaufmann E, Delahaye-Duriez A
Comput Struct Biotechnol J. 2021; 18:241-252.
PMID: 33489002
PMC: 7790737.
DOI: 10.1016/j.csbj.2019.12.006.
Bioinformatics profiling identifies seven immune-related risk signatures for hepatocellular carcinoma.
Xue F, Yang L, Dai B, Xue H, Zhang L, Ge R
PeerJ. 2020; 8:e8301.
PMID: 32518711
PMC: 7258897.
DOI: 10.7717/peerj.8301.
Identification and transfer of spatial transcriptomics signatures for cancer diagnosis.
Yoosuf N, Fernandez Navarro J, Salmen F, Stahl P, Daub C
Breast Cancer Res. 2020; 22(1):6.
PMID: 31931856
PMC: 6958738.
DOI: 10.1186/s13058-019-1242-9.
Novel Model for Comprehensive Assessment of Robust Prognostic Gene Signature in Ovarian Cancer Across Different Independent Datasets.
Bing Z, Yao Y, Xiong J, Tian J, Guo X, Li X
Front Genet. 2019; 10:931.
PMID: 31681404
PMC: 6798149.
DOI: 10.3389/fgene.2019.00931.
Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Vallon-Christersson J, Hakkinen J, Hegardt C, Saal L, Larsson C, Ehinger A
Sci Rep. 2019; 9(1):12184.
PMID: 31434940
PMC: 6704148.
DOI: 10.1038/s41598-019-48570-x.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Rodon J, Soria J, Berger R, Miller W, Rubin E, Kugel A
Nat Med. 2019; 25(5):751-758.
PMID: 31011205
PMC: 6599610.
DOI: 10.1038/s41591-019-0424-4.